First Hawaiian Bank Reduces Position in Hologic, Inc. $HOLX

Key Points

• First Hawaiian Bank reduced its stake in Hologic, Inc. by 26.6% in the first quarter, holding a total of 12,506 shares valued at $772,000 after selling 4,522 shares.
• A number of hedge funds have increased their stakes in Hologic, with Victory Capital Management raising its position by 34.4%, now owning 6.6 million shares worth over $408 million.
• Hologic reported better-than-expected earnings of $1.08 per share for the last quarter, exceeding analysts' estimates, and has set its Q4 2025 guidance between $1.090 and $1.120 EPS.

First Hawaiian Bank decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 26.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,506 shares of the medical equipment provider's stock after selling 4,522 shares during the period. First Hawaiian Bank's holdings in Hologic were worth $772,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Zions Bancorporation National Association UT bought a new position in shares of Hologic during the first quarter valued at approximately $34,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Hologic during the first quarter valued at approximately $42,000. Raiffeisen Bank International AG bought a new position in shares of Hologic during the fourth quarter valued at approximately $49,000. Allworth Financial LP increased its stake in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares in the last quarter. Finally, Larson Financial Group LLC increased its stake in shares of Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 722 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday. Morgan Stanley increased their price target on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Evercore ISI increased their price target on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and increased their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Finally, Mizuho set a $75.00 price target on shares of Hologic in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Hologic has an average rating of "Moderate Buy" and an average target price of $79.38.

Hologic Stock Performance

HOLX stock traded down $1.94 on Friday, hitting $66.33. The company had a trading volume of 8,515,121 shares, compared to its average volume of 1,762,988. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock's 50-day simple moving average is $66.47 and its 200 day simple moving average is $62.75. The stock has a market cap of $14.75 billion, a price-to-earnings ratio of 27.52, a P/E/G ratio of 2.47 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the company posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.